Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

365 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.
Jarvis MF, Honore P, Shieh CC, Chapman M, Joshi S, Zhang XF, Kort M, Carroll W, Marron B, Atkinson R, Thomas J, Liu D, Krambis M, Liu Y, McGaraughty S, Chu K, Roeloffs R, Zhong C, Mikusa JP, Hernandez G, Gauvin D, Wade C, Zhu C, Pai M, Scanio M, Shi L, Drizin I, Gregg R, Matulenko M, Hakeem A, Gross M, Johnson M, Marsh K, Wagoner PK, Sullivan JP, Faltynek CR, Krafte DS. Jarvis MF, et al. Among authors: sullivan jp. Proc Natl Acad Sci U S A. 2007 May 15;104(20):8520-5. doi: 10.1073/pnas.0611364104. Epub 2007 May 2. Proc Natl Acad Sci U S A. 2007. PMID: 17483457 Free PMC article.
ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders.
Rueter LE, Anderson DJ, Briggs CA, Donnelly-Roberts DL, Gintant GA, Gopalakrishnan M, Lin NH, Osinski MA, Reinhart GA, Buckley MJ, Martin RL, McDermott JS, Preusser LC, Seifert TR, Su Z, Cox BF, Decker MW, Sullivan JP. Rueter LE, et al. Among authors: sullivan jp. CNS Drug Rev. 2004 Summer;10(2):167-82. doi: 10.1111/j.1527-3458.2004.tb00011.x. CNS Drug Rev. 2004. PMID: 15179445 Free PMC article. Review.
Broad-spectrum efficacy across cognitive domains by alpha7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways.
Bitner RS, Bunnelle WH, Anderson DJ, Briggs CA, Buccafusco J, Curzon P, Decker MW, Frost JM, Gronlien JH, Gubbins E, Li J, Malysz J, Markosyan S, Marsh K, Meyer MD, Nikkel AL, Radek RJ, Robb HM, Timmermann D, Sullivan JP, Gopalakrishnan M. Bitner RS, et al. Among authors: sullivan jp. J Neurosci. 2007 Sep 26;27(39):10578-87. doi: 10.1523/JNEUROSCI.2444-07.2007. J Neurosci. 2007. PMID: 17898229 Free PMC article.
A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid.
El Kouhen R, Surowy CS, Bianchi BR, Neelands TR, McDonald HA, Niforatos W, Gomtsyan A, Lee CH, Honore P, Sullivan JP, Jarvis MF, Faltynek CR. El Kouhen R, et al. Among authors: sullivan jp. J Pharmacol Exp Ther. 2005 Jul;314(1):400-9. doi: 10.1124/jpet.105.084103. Epub 2005 Apr 18. J Pharmacol Exp Ther. 2005. PMID: 15837819
In vitro and in vivo characterization of a novel naphthylamide ATP-sensitive K+ channel opener, A-151892.
Gopalakrishnan M, Buckner SA, Shieh CC, Fey T, Fabiyi A, Whiteaker KL, Davis-Taber R, Milicic I, Daza AV, Scott VE, Castle NA, Printzenhoff D, London B, Turner SC, Carroll WA, Sullivan JP, Coghlan MJ, Brune ME. Gopalakrishnan M, et al. Among authors: sullivan jp. Br J Pharmacol. 2004 Sep;143(1):81-90. doi: 10.1038/sj.bjp.0705908. Epub 2004 Aug 9. Br J Pharmacol. 2004. PMID: 15302680 Free PMC article.
Pharmacological characterization of a 1,4-dihydropyridine analogue, 9-(3,4-dichlorophenyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahydro-1,8(2H,5H)-acridinedione (A-184209) as a novelK(ATP) channel inhibitor.
Gopalakrishnan M, Miller TR, Buckner SA, Milicic I, Molinari EJ, Whiteaker KL, Davis-Taber R, Scott VE, Cassidy C, Sullivan JP, Carroll WA. Gopalakrishnan M, et al. Among authors: sullivan jp. Br J Pharmacol. 2003 Jan;138(2):393-9. doi: 10.1038/sj.bjp.0705048. Br J Pharmacol. 2003. PMID: 12540531 Free PMC article.
(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. II. in vivo characterization.
Brune ME, Fey TA, Brioni JD, Sullivan JP, Williams M, Carroll WA, Coghlan MJ, Gopalakrishnan M. Brune ME, et al. Among authors: sullivan jp. J Pharmacol Exp Ther. 2002 Oct;303(1):387-94. doi: 10.1124/jpet.102.034553. J Pharmacol Exp Ther. 2002. PMID: 12235275
(-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. I. In vitro characterization.
Gopalakrishnan M, Buckner SA, Whiteaker KL, Shieh CC, Molinari EJ, Milicic I, Daza AV, Davis-Taber R, Scott VE, Sellers D, Chess-Williams R, Chapple CR, Liu Y, Liu D, Brioni JD, Sullivan JP, Williams M, Carroll WA, Coghlan MJ. Gopalakrishnan M, et al. Among authors: sullivan jp. J Pharmacol Exp Ther. 2002 Oct;303(1):379-86. doi: 10.1124/jpet.102.034538. J Pharmacol Exp Ther. 2002. PMID: 12235274
As shown in the accompanying article [Brune ME, Fey TA, Brioni JD, Sullivan JP, Williams M, Carroll WA, Coghlan MJ, and Gopalakrishnan M (2002) J Pharmacol Exp Ther 303:387-394], A-278637 suppressed myogenic contractions in vivo in a model of bladder instability wit …
As shown in the accompanying article [Brune ME, Fey TA, Brioni JD, Sullivan JP, Williams M, Carroll WA, Coghlan MJ, and Gopala …
365 results